Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
C
CDT
vs
S&P 500
S&P 500
Over the past 12 months, CDT has underperformed S&P 500, delivering a return of -100% compared to S&P 500's +16% growth.
Stocks Performance
CDT vs S&P 500
Performance Gap
CDT vs S&P 500
Performance By Year
CDT vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Conduit Pharmaceuticals Inc
Glance View
Conduit Pharmaceuticals Inc is a life sciences company that works on developing and repurposing drug candidates for hard-to-treat diseases. Its business centers on taking existing or well-understood compounds and advancing them through research, formulation, and clinical testing so they can become prescription medicines. The company does not sell a broad line of consumer products; it focuses on building a pipeline of potential therapies that may eventually be licensed or commercialized. The company’s customers are mainly pharmaceutical partners, healthcare providers, and patients who would use the medicines if they are approved. Conduit makes money through the drug development process, which can include research and development services, collaboration or licensing agreements, and future sales or royalty streams if a product reaches the market. In this industry, value is created by reducing development risk and moving promising compounds toward approved treatments. What makes Conduit different is its focus on drug repurposing and targeted development rather than discovering entirely new chemicals from scratch. That approach can shorten the path to a marketable medicine because the company starts with compounds that already have useful scientific data behind them. As a result, Conduit acts as an early-stage developer and partner in the pharmaceutical value chain, connecting laboratory science with later-stage drug commercialization.